A randomized phase II study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma: A North Central Cancer Treatment Group Study, N0775
- Citation:
- Cancer vol 119 (3) 586-592
- Year:
- 2013
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 2
- Parents:
- 580
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Experimental
- Sec. Committees:
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- Lisa A. Kottschade Vera J. Suman Domingo G. Perez Robert R. McWilliams Judith S. Kaur Thomas T. Amatruda Francois J. Geoffroy Howard M. Gross Peter A. Cohen Anthony J. Jaslowski Matthew L. Kosel Svetomir N. Markovic
- Networks:
- Study
- NCCTG-N0775
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- metastatic melanoma, chemotherapy, VEGF inhibition, combination therapy, unresectable metastatic melanoma